INDEPENDENT ANALYSIS:
API
HOLDINGS
BY POLEMARCH
h ps://[Link] h ps://[Link]
1
tt
tt
INDEPENDENT ANALYSIS
API HOLDINGS
BY POLEMARCH
2
3
© Polemarch. All rights reserved.
No part of this report may be reproduced, distributed, or transmitted in
any form or by any means, including photocopying, recording, or other
electronic or mechanical methods, without the prior written permission
of Polemarch, except in the case of brief quotations embodied in
critical reviews and certain other noncommercial uses permitted by
copyright law.
This document is the exclusive intellectual property of Polemarch
and is intended solely for the personal and con dential use of the
recipient. Unauthorised use, disclosure, or dissemination of this
material, in whole or in part, is strictly prohibited.
4
fi
DISCLAIMER
This report has been prepared by Polemarch for informational
purposes only and does not constitute an o er to sell or a
solicitation to buy any securities of API Holdings or any other
company.
The information contained herein is based on publicly available
data, internal analysis, and sources believed to be reliable;
however, Polemarch does not represent or warrant its accuracy,
completeness, or reliability. Opinions expressed are subject to
change without notice and re ect the current judgment of the
research team as of the date of this report.
Investment in unlisted and pre-IPO securities involves a high
degree of risk, including potential loss of capital and illiquidity.
Past performance is not indicative of future results. Investors are
advised to conduct their own due diligence and consult with their
nancial advisors before making any investment decisions.
Polemarch, its a liates, or employees may hold positions in or
have other interests in API Holdings or related entities and may
trade in such securities from time to time.
By accessing this report, you acknowledge and agree that
Polemarch (Mithtech Innovative Solutions PVT LTD) shall not be
liable for any direct or indirect losses arising from the use of the
information contained herein.
2
fi
ffi
fl
ff
PRICE
Unlisted Share Price: Latest transactions in the unlisted market
indicate API Holdings shares trading at approximately ₹7.00 per
share (face value ₹1.00).
FUNDAMENTAL PROFILE
Metric FY25 FY24 Change Implication
Marginal
Total ₹5,980 +3.8% revenue
₹5,759 Cr
Income Cr YoY growth, digital
health focus
Losses Cost discipline,
Operating
- ve - ve narrowed not yet
Pro t
19% pro table
- Signi cant
Net Loss -₹2,534
₹1,572 -38% YoY reduction in
(PAT) Cr
Cr net loss
Shrinking
₹6,977 -16.8%
Assets ₹8,390 Cr assets, re ects
Cr YoY
cash burn
Deleveraging,
Borrowing ₹2,234 -45.5%
₹4,098 Cr lower nance
s Cr YoY
costs
3
fi
fi
fi
fi
fl
SWOT HIGHLIGHTS
Strengths
• Largest Indian digital healthcare platform with strong brands
(PharmEasy, Thyrocare, Retailio).
• Losses narrowed sharply due to cost discipline, deleveraging, and
fewer exceptional charges.
• Investment in tech (IBM Instana for observability), reducing incident
resolution times by 30%, boosting platform reliability.
• Diagnostics and B2B segments provide margin uplift amid at
pharmacy revenue.
Weaknesses
• Still loss-making; net loss for FY25 stood at ₹1,572 crore.
• Flat topline growth for core pharmacy/ecommerce; sectoral
headwinds persist.
• Cash and equivalents dropped to ₹119 crore (-63.7% YoY), raising
liquidity concerns.
• Continued executive churn—CEO transition and multiple co-
founder departures.
Opportunities
• Ongoing capex for platform expansion and technology upgrades.
• Fundraising (₹1,700 crore NCDs in September 2025) to shore up
balance sheet and redeem previous debentures.
• Thyrocare’s strong growth can be monetised through cross-sell and
digital integration.
• Upcoming IPO could unlock value for shareholders if pro tability
stabilizes.
Threats
• Highly competitive and regulatory sector; price controls and
reimbursement challenges.
• Negative working capital, declining assets, and cash burn present
operational stress.
• Institutional sentiment is cautious—no signi cant block or insider
purchases lately, focus remains on stabilization.
4
fi
fi
fl
FINANCIAL PERFORMANCE ANALYSIS
• Revenue: ₹5,872 crore in FY25 vs ₹5,664 crore in FY24 (+3.7%
YoY).
• Expenses: Remain structurally high at ₹7,209 crore (-0.6% YoY),
keeping company in the red.
• EBITDA & Net Margin: Net margin improved from -44.1% (FY24) to
-26.3% (FY25)—losses halved on expense control.
• Finance Costs: Dropped 30% YoY to ₹506 crore due to
deleveraging.
Key Operational Metrics
• Employee expenses rose 29.9% YoY to ₹908 crore—expansion
continues, albeit measured.
• Goodwill impairment charges reduced 70% YoY, lowering
exceptional drag.
• Diagnostics segment is main growth driver, with Thyrocare
outperforming other verticals.
BALANCE SHEET & CASH FLOW HEALTH
• Equity base strengthened (₹3,272 crore, +26.4% YoY) after recent
fundraise.
• Borrowings halved to ₹2,234 crore, mitigating leverage risks.
• Cash & equivalents at ₹119 crore, implies need for recurring fund
infusion.
• Total assets declined by 17% YoY, mostly due to lower cash.
• Free cash ow not disclosed separately; capex focused on tech and
diagnostics integration.
5
fl
Recent News & Corporate Actions
• Debt raise: Issued new NCDs (₹1,700 crore) to re nance old debt.
• Leadership Transition: Rahul Guha (formerly Thyrocare) is new
CEO; several co-founders exited operational roles, signals
restructuring focus.
• Tech Collaboration: IBM Instana deployed for observability—30%
faster incident resolution, quick launch of new services.
• Thyrocare Performance: Net pro t up 30.6% YoY—group CFO
now from Thyrocare.
Shareholding & Insider Activity
• No block deals or signi cant insider buying in 2025; last major o er
for sale occurred in previous scal years.
• Institutional sentiment mixed; new fundraising indicates external
capital remains available despite operational stress.
6
fi
fi
fi
fi
ff
FORMATION, GROWTH & ACQUISITIONS (2019–2021)
• August 2020: API Holdings formed after merging founders’ portfolio
businesses (PharmEasy, Docon, Ascent, Retailio), consolidating
core digital pharmacy, B2B logistics, and EMR tech under one
entity.
• January 2021: API acquires Medlife, combining two of India’s top
online pharmacy platforms. This instantly boosts GMV and digital
reach, creating a health-tech leader.
• September 2021: API acquires Thyrocare, the largest diagnostics
company by test volumes, expanding vertically and enabling control
over lab logistics and diagnostics ful llment.
• September 2021: CCI approves TPG Growth’s acquisition of an 8%
equity stake in API Holdings, marking validation from global PE
investors.
• September 2021: Acquires Aknamed, a B2B hospital supply chain
and pharma products provider, strengthening vertical integration.
• October 2021: Acquires 49% stake in Marg ERP, adding retail tech
reach to healthcare ecosystem.
• Late 2021: Files DRHP for a ₹6,250 Cr IPO, aiming to raise funds
for debt repayment and growth. IPO is postponed due to market
volatility and regulatory headwinds; pre-IPO placements considered
but ultimately withdrawn.
BUSINESS EXPANSION, STRATEGIC SHIFTS & FUNDING (2022–
2023)
• 2022: Shifts to a holding-company led structure after failed IPO,
introducing professional management and stricter separation
between consumer, B2B, and diagnostics business lines.
• 2022: Begins cost discipline campaign leading to gradual reduction
in net losses and refocus on sustainable growth.
• 2023: Fresh fundraising e orts continue with debt and equity
rounds from Prosus, Temasek, and Indian institutional investors;
focus shifts to unit economics and pro tability ahead of possible
IPO revival.
7
ff
fi
fi
MASSIVE VALUATION RESET, LEADERSHIP REALIGNMENT &
FINANCIAL STRESS (2024)
• April 2024: Down round; API raises $216 million at a deeply cut
$700 million valuation compared to previous $5.6 billion peak. This
comes after subdued revenue and sector regulatory challenges,
triggering global investor caution.
• Q2 2024: Aggressive expense trimming results in a 15% YoY
revenue decline but net losses halve, from ₹5,211 Cr (FY23) to
₹2,533 Cr (FY24).
• 2024: Multiple co-founders (Dharmil Sheth, Dhaval Shah, Harsh
Parekh, Hardik Dedhia) depart executive roles. Only Siddharth Shah
remains in operations; others take board/advisory positions and
launch new ventures.
• Late 2024: IPO plans remain frozen; group initiates “business reset”
to prioritize diagnostics and B2B over pharmacy, strengthen
balance sheet, and regain investor trust.
RESTRUCTURING, NEW LEADERSHIP & FINANCIAL ENGINEERING
(2025)
• August 2025:
◦ Siddharth Shah steps down as CEO, transitions to Vice
Chairman and Director.
◦ Rahul Guha (CEO Thyrocare) appointed Managing Director &
CEO of API Holdings, signaling renewed focus on diagnostics
and operational rigor.
◦ Group CFO (Alok Kumar Jagnani) steps down; Vikram Gupta
(ex-EY, KPMG) becomes PharmEasy CFO. The table is set for
professional management, away from founder-driven structure.
• September 2025:
◦ API raises ₹1,700 Cr via non-convertible debentures (NCDs),
pledging 61% of Thyrocare shares as collateral. Debt used for
re nancing previous expensive borrowings and restoring
liquidity.
8
fi
◦ Focus intensi es on controlling cash burn and boosting
working capital metrics; cash position remains tight even after
re nancing.
• Q3-Q4 2025:
◦ Diagnostic revenue (Thyrocare) outpaces pharmacy and B2B,
driving margin stabilization.
◦ Reports ₹5,872 Cr revenue with net loss falling to ₹1,572 Cr,
signifying marked improvement in operational discipline.
◦ Operating results show margin improvements due to cost cuts,
but topline (pharmacy, EMR, B2B supply chain) growth
remains subdued.
◦ Institutional block deals are muted; investor and management
focus is on sector consolidation and operational pro tability
before IPO plans are revived.
9
fi
fi
fi
Key Financials & Operational Metrics (2022–2025)
Metric 2022 2023 2024 2025 Change/Context
Down, improving
Revenue (Cr) 5,729 6,644 5,564 5,872
marginally in 2025
Losses halved in
Net Loss (Cr) 3,992 5,211 2,533 1,572
2024–25
Extremely tight
Cash Position
N/A N/A N/A 119 liquidity, NCD
(Cr)
re nancing
Thyrocare Diagnostics now
N/A 687 900 1100
Revenue (Cr) driving growth
~5,0 ~90 Massive reset post
Valuation ($M) 5,600 700
00 0 down round
Financial ratios have also seen improvement, with Debt/Equity at 0.6 (vs
0.01 in prior year), current ratio dipping to 0.89, and net pro t margins
improving albeit still negative (from -6.28% to -4.2%).
10
fi
fi
Strategic Themes, Sector Impact
• Shift from founder-driven to professionally-managed leadership,
marked by CEO transition and board reshu e.
• Diagnostics and B2B supply chain become core strategic pillars,
pharmacy segment de-emphasised.
• Financial engineering (NCDs, equity raises) critical to ghting cash
burn and stabilizing the balance sheet.
• Regulatory and competitive headwinds force IPO postponement,
valuation resets, and systemic cost discipline.
• Tech investment continues via AI, IoT, and analytics for supply chain
and diagnostics; IBM Instana deployed for cloud observability and
incident management.
• Group is poised for sectoral consolidation, awaiting sustained
pro tability to revive IPO plans.
Conclusion
Over the past ve years, API Holdings has evolved from a fast-growing,
founder-driven disruptor into a professionally managed digital healthcare
conglomerate with deep vertical integration and a sharper focus on
diagnostics and supply chain e ciency. Key strategic pivots include
major acquisitions, delayed IPO ambitions, dramatic valuation resets,
founder exits, and the transition to institutional/professional
management. Financially, the group has halved losses and stabilised
operations but remains under liquidity pressure with a lean cash position.
Next phase hinges on the successful execution of diagnostic-led growth
and margin recovery for IPO revival and sustainable expansion.
PharmEasy (API Holdings) presents a mixed investment case as of
October 2025: the share price is at multi-year lows, fundamentals show
operational recovery but ongoing liquidity stress, and the digital
healthcare sector’s long-term prospects remain strong
11
fi
fi
ffi
ffl
fi
Current Valuation & Market Sentiment
• Unlisted share price: Trading around ₹5.40–₹7.00 per share, down
over 90% from 2021 highs.
• Recent trends: Prices have stabilised after reaching lows; investor
demand remains moderate with sporadic liquidity in unlisted
markets.
• 52-week range: High of ₹665 per share; current price re ects
severe correction and is now consolidating.
Fundamentals & Risk Factors
• Financial improvement: FY25 net loss more than halved to ₹1,572
crore; revenue grew modestly to ₹5,872 crore.
• Debt re nancing: Raised ₹1,700 crore via NCDs in September
2025 and pledged 61% Thyrocare stake, buying short-term relief
but highlighting past leverage risks.
• Liquidity: Still tight, with cash reserves low. Success depends on
continuing operational discipline and pro tability improvements.
• IPO timeline: No active IPO window; revival will depend on further
margin improvements and investor sentiment.
Sector Prospects & Strategic Outlook
• Digital health industry: Projected to grow at 14% CAGR with deep
long-term upside, as online pharmacy penetration remains below
global averages.
• Competitive dynamics: PharmEasy maintains leading platforms,
with strong presence in diagnostics (Thyrocare) and B2B supply;
operational improvements are visible but competitive/regulatory
headwinds persist.
• Leadership: Shift to professionally managed structure after founder
exits; institutional management now overseeing strategic reset.
12
fi
fi
fl
Buy/Hold Recommendation
• Upside potential: Valuation is attractive for long-term investors
willing to accept risk; losses are narrowing and digital health
tailwinds favor a rebound if cash burn is controlled.
• Risks: Tight liquidity, reliance on debt re nancing, lack of clear IPO
window, and the risk of further regulatory or competitive shocks
remain.
• Ideal investor pro le: Best suited for those able to hold through
volatility and wait for margin recovery/IPO; not recommended for
short-term speculation.
13
fi
fi
